CVS settles AirShield case
This article was originally published in The Tan Sheet
Executive Summary
CVS Pharmacy will pay nearly $2.8 million to settle FTC allegations it falsely advertised that its AirShield dietary supplement prevents colds, fights germs and boosts the immune system. FTC alleged the drugstore chain had no evidence to support the claims, according to a Sept. 8 FTC announcement. The allegations are similar to those FTC made against Airborne Health, Improvita Health Products and Rite Aid for similar supplements. Rite Aid paid $500,000 to settle allegations its Germ Defense ads misled consumers (1"The Tan Sheet" July 20, 2009). Airborne agreed to pay up to $30 million in consumer redress for alleged false ads (2"The Tan Sheet" Aug. 18, 2008). FTC is in litigation with Improvita
You may also be interested in...
Rite Aid settles Germ Defense case
Rite Aid Corp. agrees to pay $50,000 to settle Federal Trade Commission allegations it misled consumers by advertising the Germ Defense supplement could treat and prevent colds and flu. Rite Aid compared Germ Defense, manufactured for the chain by Improvita Health Products, to Airborne Health Inc.'s Airborne, according to FTC's complaint filed in U.S. District Court for the Middle District of Pennsylvania. Airborne Health faced similar FTC charges and agreed to pay up to $30 million in consumer redress for misleading advertising (1"The Tan Sheet" Aug. 18, 2008). FTC is currently litigating a related complaint against Cleveland-based Improvita in U.S. District Court for the Northern District of Ohio
FTC Settlement Looks To Ground Airborne Claims
Under a settlement with the Federal Trade Commission announced Aug. 14, the maker of Airborne dietary supplement products must cease unsubstantiated health-related claims and contribute up to $6.5 million to an existing consumer redress fund
Biogen Sees Improving Momentum In Slow Leqembi Launch
Sales of the company’s new drugs have a lot of growing to do to make up for older products’ declines, but Biogen highlighted signs of strength for new launches in its Q1 report.